

13<sup>th</sup> January 2022

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

**Sub: Press Release - Cipla wins the prestigious Frost & Sullivan and TERI's Sustainability 4.0 Award 2021 as "Challenger in Mega Large Business Pharma Sector"**

Dear Sir / Madam,

Please find enclosed press release dated 13<sup>th</sup> January 2022 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Encl: as above

Prepared by: Juzer Masta

## Cipla wins the prestigious Frost & Sullivan and TERI's Sustainability 4.0 Award 2021 as "Challenger in Mega Large Business Pharma Sector"

**Mumbai, India; 13 January 2022:** Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has been awarded winner as a "Challenger in Mega Large Business Pharma Sector" by Frost & Sullivan and TERI's Sustainability 4.0 Awards. The award is a testimony to Cipla's continuous efforts in the Environment, Social & Governance (ESG) space as a leader in the pharma industry. The company has been selected from a list of 50 reputed companies nominated for this award.

A joint initiative by Frost & Sullivan and TERI, the Sustainability Awards in its 12<sup>th</sup> edition evaluated companies from several sectors to understand the linkages between an organization's strategy, governance & financial performance and the social, environmental & economic context within which it operates. The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People. In this edition of the awards, the assessment also included 'Sustainability Analytics' to evaluate how companies are effectively using analytics in their sustainability management. It assessed the existing maturity of companies in three aspects mainly – Effective Data Collection, Usage of Smart Analytical Tools, and End-to-End Visibility in the value chain.

Sharing her thoughts on this award, **Geena Malhotra, Global Chief Technology Officer at Cipla** said, "We are humbled to have been selected amongst well-known companies across pharma sector for this coveted award. Sustainability is at the core of Cipla and it brings us immense pride to see that our efforts and commitment towards the Company's sustainability agenda is being recognized. We have miles to go in this journey that we have embarked upon, however, since the start we have aimed to be purposeful in all our endeavors. This recognition is reflective of the combined efforts put together by several teams that are working on the environmental, social and governance aspects of our goals. We will always continue to contribute to the Sustainable Development Goals (SDGs) through products, processes and philanthropic activities that place our stakeholders at the heart of value creation."

Recently, Cipla was also ranked one of the most sustainable healthcare companies in the Dow Jones Sustainability Emerging Markets Index. With the aim of reaching non-fossil fuel share of 40% by 2030, in January 2021, Cipla became the first pharmaceutical company in Maharashtra to invest in group captive open access solar power project of 30 MW capacity, spread across 115 acres. This has contributed to Cipla's decarbonizing goals, with the company now sourcing ~25% of its energy from renewable sources in the current year. Additionally, Cipla is also a constituent of the MSCI All Country World Index (ACWI) and has an ESG Rating of BB; as well as a constituent of FTSE4Good Index Series for the three consecutive years.

### **About Cipla:**

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT November 2021), 3rd largest in the pharma private market in South Africa (IQVIA MAT November 2021), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is

present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit [www.cipla.com](http://www.cipla.com) , or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

**For Further Information, please contact:**

**CIPLA:**

**Corporate Communications**

Heena Kanal

Email: [CorpComm@cipla.com](mailto:CorpComm@cipla.com)

**Investor Relations**

Naveen Bansal

E-Mail: [Investor.Relations@cipla.com](mailto:Investor.Relations@cipla.com)